New biosimilar for breast cancer under Real-World watch
NCT ID NCT07542496
First seen Apr 28, 2026 · Last updated Jun 13, 2026 · Updated 11 times
Summary
This study is observing how a pertuzumab biosimilar is used in everyday medical practice for people with HER2-positive breast cancer. It includes 1,000 adults receiving the drug either before surgery (neoadjuvant) or as a first treatment for cancer that has spread (metastatic). The goal is to see how well it works and how safe it is in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CAC BLIDA, Algiers, Algeria 16000
RECRUITINGAlgiers, Algeria
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Béni Messous, Algiers, Algeria 16000
RECRUITINGAlgiers, Algeria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.